Dyne Therapeutics (DYN) Stock Forecast & Price Target

Compare

415 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DYN Analyst Ratings

Strong Buy

8 Buy

2 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Dyne

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DYN Stock 12 Month Forecast

Average Price Target

$38.40

▲(96.02% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Dyne Therapeutics in the last 3 months. The average price target is $38.40 with a high forecast of $60.00 and a low forecast of $17.00. The average price target represents a 96.02% change from the last price of $19.59.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","34":"$34","61":"$61","20.5":"$20.5","47.5":"$47.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$38.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,20.5,34,47.5,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.61,23.64,26.67,29.7,32.730000000000004,35.760000000000005,38.79,41.82,44.85,47.88,50.910000000000004,53.940000000000005,56.97,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.61,21.978461538461538,23.346923076923076,24.715384615384615,26.083846153846153,27.45230769230769,28.82076923076923,30.189230769230768,31.557692307692307,32.926153846153845,34.29461538461538,35.66307692307692,37.03153846153846,{"y":38.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.61,20.33230769230769,20.054615384615385,19.776923076923076,19.49923076923077,19.22153846153846,18.943846153846152,18.666153846153847,18.388461538461538,18.11076923076923,17.833076923076923,17.555384615384614,17.27769230769231,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":29.28,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.56,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.22,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.61,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.23,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.99,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.7,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.68,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.05,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.58,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.61,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$60.00

Average Price Target$38.40

Lowest Price Target$17.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Gavin Clark-Gartner

Evercore ISI

$38→$36

Buy

83.77%

Upside

Reiterated

12/15/25

Dyne Therapeutics price target lowered to $36 from $38 at Evercore ISIDyne Therapeutics price target lowered to $36 from $38 at Evercore ISI

Paul Matteis

Stifel Nicolaus

$36

Buy

83.77%

Upside

Reiterated

12/15/25

Dyne Therapeutics (DYN) Gets a Buy from Stifel Nicolaus

Andreas Argyrides

Oppenheimer

$11→$40

Buy

104.19%

Upside

Upgraded

12/10/25

Dyne Therapeutics upgraded to Outperform from Perform at OppenheimerDyne Therapeutics upgraded to Outperform from Perform at Oppenheimer

Michael Ulz

Morgan Stanley

$46→$50

Buy

155.23%

Upside

Reiterated

12/09/25

Dyne Therapeutics (DYN) Receives a Buy from Morgan Stanley

William Pickering

Bernstein

$21→$23

Hold

17.41%

Upside

Reiterated

12/09/25

Dyne Therapeutics price target raised to $23 from $21 at BernsteinDyne Therapeutics price target raised to $23 from $21 at Bernstein

Ananda Ghosh

H.C. Wainwright

$46→$60

Buy

206.28%

Upside

Reiterated

12/08/25

Dyne Therapeutics price target raised to $60 from $46 at H.C. WainwrightDyne Therapeutics price target raised to $60 from $46 at H.C. Wainwright

Francois Brisebois

LifeSci Capital

$40→$44

Buy

124.60%

Upside

Reiterated

12/08/25

Analysts Are Bullish on Top Healthcare Stocks: BioNTech SE (BNTX), Icon (ICLR)

Edward Tenthoff

Piper Sandler

$48

Buy

145.02%

Upside

Reiterated

12/01/25

Dyne Therapeutics (DYN) Gets a Buy from Piper Sandler

Tessa Romero

J.P. Morgan

$18→$17

Hold

-13.22%

Downside

Reiterated

11/14/25

Dyne Therapeutics price target lowered to $17 from $18 at JPMorganDyne Therapeutics price target lowered to $17 from $18 at JPMorgan

Luca Issi

RBC Capital

$30

Buy

53.14%

Upside

Reiterated

11/05/25

RBC Capital Remains a Buy on Dyne Therapeutics (DYN)

Martin Auster

Raymond James

$31→$35

Buy

78.66%

Upside

Reiterated

08/25/25

Dyne Therapeutics upgraded to Strong Buy from Outperform at Raymond JamesDyne Therapeutics upgraded to Strong Buy from Outperform at Raymond James

Louise Chen

Scotiabank

$50

Buy

155.23%

Upside

Reiterated

07/29/25

Dyne Therapeutics (DYN) Gets a Buy from Scotiabank

Keay Nakae

Chardan Capital

$50→$38

Buy

93.98%

Upside

Reiterated

07/28/25

Chardan Capital Sticks to Its Buy Rating for Dyne Therapeutics (DYN)

Catherine Novack

JonesTrading

$30

Buy

53.14%

Upside

Initiated

06/25/25

Dyne Therapeutics initiated with a Buy at JonesResearchDyne Therapeutics initiated with a Buy at JonesResearch

Brian Skorney

Robert W. Baird

$46→$32

Buy

63.35%

Upside

Reiterated

06/18/25

Dyne Therapeutics price target lowered to $32 from $46 at BairdDyne Therapeutics price target lowered to $32 from $46 at Baird

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Gavin Clark-Gartner

Evercore ISI

$38→$36

Buy

83.77%

Upside

Reiterated

12/15/25

Dyne Therapeutics price target lowered to $36 from $38 at Evercore ISIDyne Therapeutics price target lowered to $36 from $38 at Evercore ISI

Paul Matteis

Stifel Nicolaus

$36

Buy

83.77%

Upside

Reiterated

12/15/25

Dyne Therapeutics (DYN) Gets a Buy from Stifel Nicolaus

Andreas Argyrides

Oppenheimer

$11→$40

Buy

104.19%

Upside

Upgraded

12/10/25

Dyne Therapeutics upgraded to Outperform from Perform at OppenheimerDyne Therapeutics upgraded to Outperform from Perform at Oppenheimer

Michael Ulz

Morgan Stanley

$46→$50

Buy

155.23%

Upside

Reiterated

12/09/25

Dyne Therapeutics (DYN) Receives a Buy from Morgan Stanley

William Pickering

Bernstein

$21→$23

Hold

17.41%

Upside

Reiterated

12/09/25

Dyne Therapeutics price target raised to $23 from $21 at BernsteinDyne Therapeutics price target raised to $23 from $21 at Bernstein

Ananda Ghosh

H.C. Wainwright

$46→$60

Buy

206.28%

Upside

Reiterated

12/08/25

Dyne Therapeutics price target raised to $60 from $46 at H.C. WainwrightDyne Therapeutics price target raised to $60 from $46 at H.C. Wainwright

Francois Brisebois

LifeSci Capital

$40→$44

Buy

124.60%

Upside

Reiterated

12/08/25

Analysts Are Bullish on Top Healthcare Stocks: BioNTech SE (BNTX), Icon (ICLR)

Edward Tenthoff

Piper Sandler

$48

Buy

145.02%

Upside

Reiterated

12/01/25

Dyne Therapeutics (DYN) Gets a Buy from Piper Sandler

Tessa Romero

J.P. Morgan

$18→$17

Hold

-13.22%

Downside

Reiterated

11/14/25

Dyne Therapeutics price target lowered to $17 from $18 at JPMorganDyne Therapeutics price target lowered to $17 from $18 at JPMorgan

Luca Issi

RBC Capital

$30

Buy

53.14%

Upside

Reiterated

11/05/25

RBC Capital Remains a Buy on Dyne Therapeutics (DYN)

Martin Auster

Raymond James

$31→$35

Buy

78.66%

Upside

Reiterated

08/25/25

Dyne Therapeutics upgraded to Strong Buy from Outperform at Raymond JamesDyne Therapeutics upgraded to Strong Buy from Outperform at Raymond James

Louise Chen

Scotiabank

$50

Buy

155.23%

Upside

Reiterated

07/29/25

Dyne Therapeutics (DYN) Gets a Buy from Scotiabank

Keay Nakae

Chardan Capital

$50→$38

Buy

93.98%

Upside

Reiterated

07/28/25

Chardan Capital Sticks to Its Buy Rating for Dyne Therapeutics (DYN)

Catherine Novack

JonesTrading

$30

Buy

53.14%

Upside

Initiated

06/25/25

Dyne Therapeutics initiated with a Buy at JonesResearchDyne Therapeutics initiated with a Buy at JonesResearch

Brian Skorney

Robert W. Baird

$46→$32

Buy

63.35%

Upside

Reiterated

06/18/25

Dyne Therapeutics price target lowered to $32 from $46 at BairdDyne Therapeutics price target lowered to $32 from $46 at Baird

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Dyne Therapeutics

1 Month

xxx

Success Rate

9/15 ratings generated profit

Average Return

+0.53%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +0.53% per trade.

3 Months

xxx

Success Rate

15/24 ratings generated profit

Average Return

+9.78%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +9.78% per trade.

1 Year

Keay NakaeChardan Capital

Success Rate

10/15 ratings generated profit

Average Return

+53.22%

reiterated a buy rating 5 months ago

Copying Keay Nakae's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +53.22% per trade.

2 Years

xxx

Success Rate

11/19 ratings generated profit

Average Return

+77.18%

reiterated a xxx

rating 16 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 57.89% of your transactions generating a profit, with an average return of +77.18% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DYN Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DYN has received 18 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. DYN average Analyst price target in the past 3 months is 38.40.

Each month's total comprises the sum of three months' worth of ratings.

DYN Financial Forecast

DYN Earnings Forecast

Next quarter’s earnings estimate for DYN is -$0.77 with a range of -$0.94 to -$0.59. The previous quarter’s EPS was -$0.76. DYN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year DYN has Performed in-line its overall industry.

No data currently available

DYN Sales Forecast

Next quarter’s sales forecast for DYN is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. DYN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year DYN has Performed in-line its overall industry.

DYN Stock Forecast FAQ

What is DYN’s average 12-month price target, according to analysts?

Based on analyst ratings, Dyne Therapeutics’s 12-month average price target is 38.40.

What is DYN’s upside potential, based on the analysts’ average price target?

Dyne Therapeutics has 96.02% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is DYN a Buy, Sell or Hold?

Dyne Therapeutics has a consensus rating of Strong Buy which is based on 8 buy ratings, 2 hold ratings and 0 sell ratings.

What is Dyne Therapeutics’s price target?

The average price target for Dyne Therapeutics is 38.40. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $60.00 ,the lowest forecast is $17.00. The average price target represents 96.02% Increase from the current price of $19.59.

What do analysts say about Dyne Therapeutics?

Dyne Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of DYN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Dyne Therapeutics (DYN) Stock Forecast & Price Target

DYN Analyst Ratings

DYN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Dyne Therapeutics

DYN Analyst Recommendation Trends

DYN Financial Forecast

DYN Earnings Forecast

DYN Sales Forecast

DYN Stock Forecast FAQ

Detailed List of Analyst Forecasts